DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC; 2008.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–199. doi:10.1111/j.1365-2141.1982.tb08475.x. PMID:6952920
   PubMed Web of Science ®Google Scholar
• Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375–383. doi:10.3324/haematol.2010.030957. PMID:21109693
   PubMed Web of Science ®Google Scholar
• Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111–1115. doi:10.1002/ajh.23846. PMID:25195656
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788–800. doi:10.1111/j.1365-2141.2009.07697.x. PMID:19388938
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676–1681. doi:10.3324/haematol.2009.011205. PMID:19797729
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(19):2428–2436. doi:10.1200/JCO.2012.47.3314.
   PubMed Web of Science ®Google Scholar
• Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–1417. doi:10.1182/blood-2016-05-714030. PMID:27385790
   PubMed Web of Science ®Google Scholar
• Issa J-P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am. 2010;24(2):317–330. doi:10.1016/j.hoc.2010.02.007. PMID:20359628
   PubMed Web of Science ®Google Scholar
• Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 2007;138(1):3–11. doi:10.1111/j.1365-2141.2007.06604.x. PMID:17489980
   PubMed Web of Science ®Google Scholar
• Lehmann U, Brakensiek K, Kreipe H. Role of epigenetic changes in hematological malignancies. Ann Hematol. 2004;83(3):137–152. doi:10.1007/s00277-003-0798-7. PMID:15064862
   PubMed Web of Science ®Google Scholar
• Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20(1):1–13. doi:10.1016/j.blre.2005.01.006. PMID:16426940
   PubMed Web of Science ®Google Scholar
• Bullinger L, Ehrich M, Döhner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115(3):636–642. doi:10.1182/blood-2009-03-211003. PMID:19903898
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13–27. doi:10.1016/j.ccr.2009.11.020. PMID:20060365
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(4):605–613. doi:10.1200/JCO.2009.23.4781.
   PubMed Web of Science ®Google Scholar
• Tessema M, Länger F, Dingemann J, et al. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 2003;17(5):910–918. doi:10.1038/sj.leu.2402891. PMID:12750705
   PubMed Web of Science ®Google Scholar
• Aucagne R, Droin N, Paggetti J, et al. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011;121(6):2361–2370. doi:10.1172/JCI45213. PMID:21537084
   PubMed Web of Science ®Google Scholar
• Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5):1857–1872. doi:10.1172/JCI78752. PMID:25822018
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839–843. doi:10.1038/nature09586. PMID:21057493
   PubMed Web of Science ®Google Scholar
• Yamazaki J, Jelinek J, Lu Y, et al. TET2 mutations affect Non-CpG Island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Res. 2015;75(14):2833–2843. doi:10.1158/0008-5472.CAN-14-0739. PMID:25972343
   PubMed Web of Science ®Google Scholar
• Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7(2):201–207. doi:10.4161/epi.7.2.19015. PMID:22395470
   PubMed Web of Science ®Google Scholar
• Diesch J, Zwick A, Garz A-K, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8:71. doi:10.1186/s13148-016-0237-y. PMID:27330573
   PubMed Web of Science ®Google Scholar
• Palomo L, Garcia O, Arnan M, et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget. 2016;7(35):5702–57035. doi:10.18632/oncotarget.10937 PMID:27486981.
   Google Scholar
• Brakensiek K, Länger F, Schlegelberger B, et al. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol. 2005;130(2):209–217. doi:10.1111/j.1365-2141.2005.05590.x. PMID:16029449
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76(1):23–32. doi:10.1111/j.1600-0609.2005.00559.x. PMID:16343268
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315–1325. doi:10.1182/blood-2008-06-163246. PMID:18832655
   PubMed Web of Science ®Google Scholar
• Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824–3831. doi:10.1182/blood-2011-05-352039. PMID:21828134
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448–3458. doi:10.1182/blood-2009-01-200519. PMID:19652201
   PubMed Web of Science ®Google Scholar
• Yu J, Tao Q, Cheng YY, et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer. 2009;115(1):49–60. doi:10.1002/cncr.23989. PMID:19051296
   PubMed Web of Science ®Google Scholar
• Li J, Huang KL, Zhang T, et al. Pan-cancer methylation and expression profiling of adenocarcinomas revealed epigenetic silencing in the WNT signaling pathway. Neoplasma. 2016;63(2):208–214. doi:10.4149/205_150601N306. PMID:26774141
   PubMed Web of Science ®Google Scholar
• Liu S, Chen X, Chen R, et al. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget. 2017;8(22):36354–36367. doi:10.18632/oncotarget.16754. PMID:PMC5482660
   PubMedGoogle Scholar
• Grövdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010;150(3):293–302. doi:10.1111/j.1365-2141.2010.08235.x. PMID:20497178
   PubMed Web of Science ®Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843–850. doi:10.1038/nature03319. PMID:15829953
   PubMed Web of Science ®Google Scholar
• Del Rey M, O'Hagan K, Dellett M, et al. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia. 2013;27(3):610–618. doi:10.1038/leu.2012.253. PMID:22936014
   PubMed Web of Science ®Google Scholar
• Potapova A, Hasemeier B, Römermann D, et al. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. Eur J Haematol. 2010;84(4):298–303. doi:10.1111/j.1600-0609.2009.01389.x. PMID:20002157
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang F, Li S, et al. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br J Haematol. 2014;165(5):649–658. doi:10.1111/bjh.12811. PMID:24601943
   PubMed Web of Science ®Google Scholar
• Novak P, Jensen T, Oshiro MM, et al. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res. 2008;68(20):8616–8625. doi:10.1158/0008-5472.CAN-08-1419. PMID:18922938
   PubMed Web of Science ®Google Scholar
• Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006;20(23):3199–3214. doi:10.1101/gad.1486806. PMID:17158740
   PubMed Web of Science ®Google Scholar
• Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell. 1999;97(6):779–790. doi:10.1016/S0092-8674(00)80789-8. PMID:10380929
   PubMed Web of Science ®Google Scholar
• Wang K-H, Lin C-J, Liu C-J, et al. Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV. Cancer Med. 2015;4(1):43–55. doi:10.1002/cam4.335. PMID:25418975
   PubMed Web of Science ®Google Scholar
• Milani L, Lundmark A, Kiialainen A, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood. 2010;115(6):1214–1225. doi:10.1182/blood-2009-04-214668. PMID:19965625
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868–876. doi:10.1038/sj.leu.2404624. PMID:17361230
   PubMed Web of Science ®Google Scholar
• Cosialls AM, Santidrián AF, Coll-Mulet L, et al. Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe amplification. Epigenomics. 2012;4(5):491–501. doi:10.2217/epi.12.40. PMID:23130831
   PubMed Web of Science ®Google Scholar
• Magnani G, Furlan D, Sahnane N, et al. Molecular features and methylation status in early onset (≤40 Years) colorectal cancer: A population based, Case-control study. Gastroenterol Res Pract. 2015;2015:132190. doi:10.1155/2015/132190. PMID:26557847
   PubMedGoogle Scholar
• Stirzaker C, Zotenko E, Song JZ, et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Commun. 2015;6:5899. doi:10.1038/ncomms6899. PMID:25641231
   PubMed Web of Science ®Google Scholar
• Mžik M, Chmelařová M, John S, et al. Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma. Clin Chem Lab Med. 2016;54(12):1971–1980. doi:10.1515/cclm-2015-1198. PMID:27171388
   PubMed Web of Science ®Google Scholar
• Strathdee G, Holyoake TL, Sim A, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(17):5048–5055. doi:10.1158/1078-0432.CCR-07-0919.
   PubMed Web of Science ®Google Scholar
• Jost E, Lin Q, Weidner CI, et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia. 2014;28(6):1227–1234. doi:10.1038/leu.2013.362. PMID:24280869
   PubMed Web of Science ®Google Scholar
• Qu X, Davison J, Du L, et al. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics. 2015;10(6):526–535. doi:10.1080/15592294.2015.1048060. PMID:25996682
   PubMed Web of Science ®Google Scholar
• Spencer DH, Young MA, Lamprecht TL, et al. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia. 2015;29(6):1279–1289. doi:10.1038/leu.2015.6. PMID:25600023
   PubMed Web of Science ®Google Scholar
• Chen S-L, Liu L-L, Lu S-X, et al. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017;11(9):1225–1240. doi:10.1002/1878-0261.12090. PMID:28580773
   PubMed Web of Science ®Google Scholar
• Pérez C, Martínez-Calle N, Martín-Subero JI, et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PloS One. 2012;7(2):e31605. doi:10.1371/journal.pone.0031605. PMID:22328940
   PubMed Web of Science ®Google Scholar
• Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–3015. doi:10.1182/blood-2012-08-452938. PMID:23372164
   PubMed Web of Science ®Google Scholar
• Shaffer LG, McGowan-Jordan J, Schmid M. ISCN2013: An international system for human cytogenetic nomenclature. Basel (Switzerland): Karger; 2013.
   Google Scholar
• Palomo L, Xicoy B, Garcia O, et al. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases: SNP-a karyotyping impact on the diagnosis and outcome of patients with chronic myelomonocytic leukemia. Am J Hematol. 2016;91(2):185–192. doi:10.1002/ajh.24227. PMID:26509444
   PubMed Web of Science ®Google Scholar
• Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6(6):692–702. doi:10.4161/epi.6.6.16196. PMID:21593595
   PubMed Web of Science ®Google Scholar
• Assenov Y, Müller F, Lutsik P, et al. Comprehensive analysis of DNA methylation data with RnBeads. Nat Methods. 2014;11(11):1138–1140. doi:10.1038/nmeth.3115. PMID:25262207
   PubMed Web of Science ®Google Scholar
• Ma Z, Teschendorff AE. A variational Bayes beta mixture model for feature selection in DNA methylation studies. J Bioinform Comput Biol. 2013;11(4):1350005. doi:10.1142/S0219720013500054. PMID:23859269
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108. doi:10.1038/nprot.2008.73. PMID:18546601
   PubMed Web of Science ®Google Scholar